EMUC Congress | Conference

Optimizing Adjuvant Therapy in Renal Cell Carcinoma

November 20th 2017

Patients with high-risk renal cell carcinoma who harbor early systemic dissemination with very poor survival prognosis may derive some benefit from adjuvant therapy.

Immunotherapy Continues to Shape Future Bladder Cancer Paradigm

November 20th 2017

Maria De Santis, MD, discusses the findings of KEYNOTE-045 and the future of immunotherapy in the treatment landscape of bladder cancer.

Dr. Capitanio Discusses Adjuvant Therapy for High-Risk Kidney Cancer

November 19th 2017

Umberto Capitanio, MD, FEBU, department of Urology, San Raffaele Scientific Institute, University Vita-Salute San Raffaele, discusses adjuvant therapy for patients with high-risk kidney cancer without metastases.

Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

November 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

Next Steps in Bladder Cancer to Include Combination Immunotherapy

November 19th 2017

Andrea Necchi, MD, discusses the evolution of bladder cancer therapies, the challenge with the currently available agents, and the next steps and clinical trials being conducted in the field.

Molecular Subtypes Prognostic for OS, DFS in Clear-Cell RCC

November 18th 2017

Four molecular subtypes of clear-cell renal cell carcinoma were prognostic for outcomes after metastasectomy, with striking differences seen in overall survival and disease-free survival between each of the groups.

Dr. Junker on Need to Identify Biomarkers to Predict Response to RCC Treatment

November 18th 2017

Kerstin Junker, MD, associate professor, Department of Urology, Universit

Dr. Mason on the Significance of the PROTECT Study in Prostate Cancer

November 18th 2017

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significance of the PROTECT study in prostate cancer during the 2017 EMUC Congress.

LDH a Predictor for OS in mCRPC Following Radium-223

November 18th 2017

Log LDH was the strongest predictor for overall survival with radium-223 for men with metastatic castration resistant prostate cancer.

Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC

November 18th 2017

An extension in overall survival seen with the combination of nivolumab and ipilimumab has completely changed the standard of care for patients with metastatic renal cell carcinoma.

Dr. Volpe Discusses the Management of Localized Kidney Cancer

November 18th 2017

Alessandro Volpe, MD, University of Eastern Piedmont Hospital, Maggiore Della Carita Hospital, Novara, Italy, discusses the management of locally advanced kidney cancer.

Pembrolizumab, Atezolizumab New Standards for Bladder Cancer

November 18th 2017

A wealth of new clinical trial data for immune checkpoint inhibitors has recently been reported for the treatment of patients with metastatic muscle-invasive urothelial carcinoma.

Combining Partial Metastasectomy With Systemic Treatment Beneficial in mRCC

November 18th 2017

The addition of incomplete metastasectomy to systemic therapy improved median overall survival by 3 months in patients with metastatic renal cell carcinoma.

PI-RADS Offers Prognostic Advantage Over mpMRI Alone for Prostatectomy

November 17th 2017

Use of the novel prostate imaging reporting and data system enhanced the ability to determine prostate cancer stage versus standard multiparametric MRI alone, offering advantages for deciding the extent of resection needed during an endoscopic radical prostatectomy.

Dr. Necchi on Impact of PD-1 Inhibition in Bladder Cancer

November 17th 2017

Andrea Necchi, MD, a medical oncologist at the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, discusses the impact of PD-1 inhibition in bladder cancer as well as the promise with combination strategies.